Lifecore Biomedical Earnings Call Transcripts
Fiscal Year 2026
-
The company has transformed into a pure-play life sciences CDMO, focusing on sterile injectables and hyaluronic acid fermentation. With reinforced mid-term revenue and margin targets, a robust late-stage pipeline, and new tech transfer agreements, growth is driven by reshoring trends and expanding partnerships. Capacity utilization and operational efficiency are set to improve through 2029.
-
Revenue and EBITDA margins grew strongly in 2025, driven by pipeline expansion, operational efficiencies, and new business wins. 2026 guidance anticipates stable revenue and margin progression, with significant growth expected from 2027 as major customer demand and late-stage pipeline launches accelerate.
-
Q3 2025 saw 26% revenue growth, improved margins, and new business wins, with a strong late-stage pipeline and cost reductions driving a positive outlook. Guidance for the transition period was reaffirmed, with further margin expansion and revenue growth expected.
Fiscal Year 2025
-
Transitioning to a standalone CDMO, the company has invested in capacity, revamped leadership, and implemented new commercial strategies. With only 20% of $300M capacity utilized, a strong late-stage pipeline, and a focus on margin expansion, it targets 12% CAGR and 25%+ EBITDA margins midterm.
-
Lifecore Biomedical outlined an aggressive growth strategy, leveraging recent capital investments and a revamped commercial approach to target a 12% revenue CAGR and >25% EBITDA margins over the next 3–4 years. The company is well-positioned in a growing CDMO market, with a robust late-stage pipeline and improved liquidity.
-
Sterile injectables CDMO is expanding into biologics and peptides, leveraging technical and regulatory strengths. A new leadership team drives a three-pronged growth strategy, with major investments completed and a focus on high-value, recurring revenue. Quality and global compliance underpin strong customer relationships.
-
Fiscal 2025 saw strong operational and strategic progress, with new customer wins, improved productivity, and a strengthened balance sheet. Revenue was stable year-over-year, while adjusted EBITDA met guidance. Outlook remains positive with a robust late-stage pipeline and margin improvements expected.
-
Q3 revenue was $35.2M, down 2% year-over-year, with a net loss of $14.8M due to lower CDMO revenues and one-time items. Guidance for FY25 is reiterated, targeting $126.5M–$130M in revenue and $19M–$21M in adjusted EBITDA. Operational efficiencies and new customer wins support future growth.
-
A leading CDMO in sterile injectables, the company has completed its transformation, expanded capacity, and set a 12% midterm revenue CAGR target. Growth is driven by guaranteed customer commitments, a robust late-stage pipeline, and operational efficiencies, with a long-term revenue goal of $300 million.
-
Q2 saw 8% revenue growth, improved gross margins, and a strengthened balance sheet via PIPE financing and credit facility restructuring. The business pipeline expanded, with 50+ opportunities and 30% from large pharma, while guidance for revenue and EBITDA was reiterated.
-
Q1 revenue grew slightly year-over-year, with gross profit doubling due to favorable mix and pricing, but net loss widened on higher SG&A and interest expenses. New customer wins, expanded capacity, and a $24.3M capital raise support reaffirmed FY25 guidance and improved liquidity.
Fiscal Year 2024
-
A strategic transformation has positioned the company as a leading CDMO, targeting 12%+ revenue CAGR and over 25% EBITDA margins in the midterm. Growth will be driven by Fill/Finish expansion, late-stage pipeline commercialization, and operational efficiencies, with significant new business opportunities and industry tailwinds supporting the outlook.
-
The company is expanding its sterile fill-finish capabilities, doubling capacity with new technology and targeting growth in biologics and pre-filled syringes. Market trends and regulatory changes are expected to drive new domestic opportunities, with leadership optimistic about future growth.
-
Revenue grew 24.2% to $128.3M in fiscal 2024, with gross margin up to 32.6% and Adjusted EBITDA up 82%. Fiscal 2025 guidance is flat, reflecting customer inventory headwinds and no new launches, but cost reductions and new capabilities position the company for future growth.